Biogen and Samsung Bioepis Develop Biosimilars for RA Treatment
News, rheumatoid arthritis
Biogen and Samsung Bioepis Co., Ltd. have three exciting new anti-tumor necrosis factor (anti-TNF) biosimilars under development to treat patients with rheumatoid arthritis. Representatives from the companies will present data at ... Read more